DB15655InvestigationalVaccines
Ad5-nCoV is a recombinant adenovirus type-5 vector (Ad5) vaccine currently being investigated for prophylaxis against SARS-CoV-2. It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute... It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906) with an expected completion in...
- Also known as
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Resolves to
Compound
What you can answer from here — as of April 02, 2025
Which companies are running trials of Ad5-nCoV, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account